On June 2, 2023, at ASCO, CancerX, a public-private partnership co-hosted by Moffitt Cancer Center and the Digital Medicine Society (DiMe), along with the Office for the National Coordinator for Health Information Technology (ONC) and the Office of the Assistant Secretary for Health (OASH), announced its founding members. VivoSense is proud to be among other organizations striving to eradicate cancer!
CancerX was initially introduced by U.S. President Joe Biden and Dr. Jill Biden in February 2023 as a component of The White House’s renewed national Cancer Moonshot initiative. This public-private partnership aims to bring together diverse stakeholders and innovators to leverage the potential of digital innovation in designing a future free from the burden of cancer. By establishing best practices, building capacity, and showcasing the impact of innovation, CancerX will improve the lives of everyone affected by cancer.
Why VivoSense Joined CancerX
The wealth of patient-specific real-world data obtained through wearable sensors and the opportunity to translate real-world data into actionable information that advances earlier diagnosis and precise treatment options in cancer patients is a huge step forward for cancer research.
“CancerX is so timely: As cancer survivorship grows, so does the need for patient-centric, quality-of-life-relevant evidence tools. VivoSense is excited to share our experience developing digital measures for oncology clinical trials and learn from the many great partners who have joined.”
~ Ieuan Clay, PhD, Director of Science
In 2020, VivoSense was awarded an NIH/NCI Phase 1 contract to collaborate with key opinion leaders and build an end-to-end data informatics platform explicitly designed for cancer research and care communities. The VivoSense team is excited to be part of CancerX to continue advancing the power of wearable sensors and digital biomarkers and revolutionize cancer research and care.